Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
WDFY3-AS2
Specific or universal ncRNAs
Specific ncRNAs
Class
Long noncoding RNA
Biomarker
None
Biomarker application
Upstream regulatory factors
Not available
Downstream target
hsa-miR-139-5p/SDC4
Cancer name
Ovarian Cancer
Cancer site
qRT-PCR,Western blot,Dual-luciferase assay
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis
Tissue resource
osteosarcoma tumor and paracancerous tissues
human osteosarcoma cell lines A2780
human cisplatin-resistant osteosarcoma cell lines A2780/DDP
Experiment
None
Institute
The First Affiliated Hospital of Anhui Medical University
American Type Culture Collection
Country
China
United States
Continent
Asia
North Amercian
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.